Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder

Next Previous
Search
Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NSI 189 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Neuralstem; Seneca Biopharma

    • Most Recent Events

    • 02 Apr 2018 Status changed from active, no longer recruiting to completed, according to a Neuralstem media release.
    • 05 Dec 2017 Results published in the Neuralstem Media Release
    • 13 Nov 2017 According to a Neuralstem media release, the company will present additional clinical data at the American College of Neuropsychopharmacology (Dec 2017) and will have a Post-phase II meeting with the FDA in the first half of 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top